Clinical trials: Diabetic Kidney Disease (DKD)
Diabetic Kidney Disease, Type2 Diabetes
Determining Serum and Urinary Levels of miRNA 192 and miRNA 25 in Patients With and Without Type 2 Diabetes.
Diabetes kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in western countries and its incidence is worryingly increasing worldwide.
- Trial name
- NCT04176276
- Testing
- no interventions required.
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Pisa
Healthy Adult Participants, Diabetic Kidney Disease
Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439…
- Trial name
- NCT07473323
- Testing
- MTX-439
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Mediar Therapeutics
Diabetic Nephropathy Type 2
the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD
Efficacy and Safety of treatment with Traditional Chinese Medicine ShenqiDihuang Decoctions in Patients with middle stage of Diabetic Kidney Disease.
- Trial name
- NCT03681249
- Testing
- ShenqiDihuang Decoction
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Type 1 Diabetes, T1D Heart Failure
Precision T1D Platform - New Therapies for Cardio-Renal Complications
Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health \& Science University Center of Excellence (CoE) to address cardio-renal complications in T1D.
- Conditions
- Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
- Trial name
- NCT07594145
- Testing
- Finerenone, Sotagliflozin
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Oregon Health and Science University
Diabetic Kidney Disease (DKD)
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2
Using the practical randomized controlled trial designed by Zelen, the subjects were randomly divided into the experimental group and the control group.
- Trial name
- NCT07034807
- Testing
- the traditional Chinese medicine prescription ' Shenzhuo Decoction ', basic treatment
- Where
- 5 sites in China
- Volunteers
- 228 people
- Sponsor
- Liu Hongfang
Diabetic Nephropathy
Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD
Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease worldwide and is associated with a high risk of cardiovascular events and mortality.
- Trial name
- NXT-DKD (NCT07698223)
- Testing
- Naoxintong Capsule
- Where
- 8 sites in China
- Volunteers
- 410 people
- Sponsor
- Chen Xiangmei
Glomerulonephritis, Membranous, Diabetic Nephropathies
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Influence factors and preliminary mechanism of high incidence of thrombotic events in patients with idiopathic membranous nephropathy and diabetes kidney disease
- Conditions
- Glomerulonephritis, Membranous, Diabetic Nephropathies, Thrombelastography, Thromboembolism
- Trial name
- NCT05656963
- Testing
- Grouping based on previous laboratory results, no intervention.
- Where
- China
- Volunteers
- 741 people
- Sponsor
- Yipeng Liu
Diabetic Kidney Disease (DKD)
Rubix LS Diabetic Kidney Disease (DKD) Registry Study
Diabetic kidney disease (DKD) is a common complication of type 2 diabetes that can lead to kidney failure and increases the risk of cardiovascular disease.
- Trial name
- NCT07348718
- Testing
- Kidney-Protective Therapies Used in Routine Care
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Rubix LS
T2DM (Type 2 Diabetes Mellitus), Metformin
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
This multicenter, randomized, open-label, controlled study will assess the efficacy of the SGLT2 inhibitor tofogliflozin on Urine Albumin-to-Creatinine Ratio (UACR) compared to metformin in patients with type 2 diabetes with…
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Metformin, SGLT2-Inhibitors
- Trial name
- TRUTH-DKD (NCT05469659)
- Testing
- Tofogliflozin, Metformin
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Shinshu University
Diabetic Kidney Disease
Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD
1. Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease. 2. To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on…
- Trial name
- NCT06069076
- Testing
- cathepsin S and chromogranin A
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetic Kidney Disease (DKD)
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria…
- Trial name
- NCT04419467
- Testing
- CSL346
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 114 people
- Sponsor
- CSL Behring
Diabetic Kidney Disease (DKD)
Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease
The goal of this single-arm, open-label clinical trial is to evaluate the effects of subcutaneous autologous dendritic cell (DC) and lymphocyte administration on albuminuria and endothelial dysfunction in Type 2 Diabetes Mellitus…
- Trial name
- NCT06866158
- Testing
- Dendritic cell immunotherapy
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- PT. JES Kasih Nusantara Sejahterah
Diabetic Kidney Disease (DKD)
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.
- Trial name
- ANCHOR-POC (NCT07271186)
- Testing
- ALN-ANG3, Evinacumab
- Where
- 59 sites in United States
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Kidney Disease
A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients
The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.
- Trial name
- NCT06666283
- Testing
- AP303 150μg
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Alebund Pharmaceuticals
Diabetic Kidney Disease (DKD)
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1
In order to reduce the clinical demand for kidney dialysis rate of Diabetic Kidney Disease（DKD） patients, a bidirectional cohort study of 4472 patients with DKD (Qi deficiency and collateral stasis syndrome) was carried out based…
- Trial name
- NCT07032116
- Where
- 5 sites in China
- Volunteers
- 4,472 people
- Sponsor
- Liu Hongfang
Diabetes, Hypertension
Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)
Diabetic kidney disease (DKD) is associated with high rates of cardiovascular events and death. In addition, DKD is the major cause of end-stage renal disease (ESRD) in the United States.
- Conditions
- Diabetes, Hypertension, Diabetic Kidney Disease
- Trial name
- STOP-DKD (NCT01829256)
- Testing
- Pharmacist telehealth intervention
- Where
- United States
- Volunteers
- 285 people
- Sponsor
- Duke University
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Low Carbohydrate Diet in Diabetic Kidney Disease
The current population of type 2 diabetes mellitus (T2DM) worldwide is over 200 million and Malaysia contributes to 1.2% of that number.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Obesity
- Trial name
- NCT04931030
- Testing
- Dietary advice
- Where
- Malaysia
- Volunteers
- 30 people
- Sponsor
- Universiti Teknologi Mara
Autosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD)
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
This is a prospective, clinical, multicentre study aimed to collect biological samples and study microbiota from subjects suffering from chronic kidney disease and from healthy volunteers.
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), IgA Nephropathy (IgAN)
- Trial name
- BIOMIS-Nefro (NCT04689074)
- Testing
- Biological sample collection, Questionnaire, Medical examination
- Where
- 2 sites in Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Diabetic Kidney Disease
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
This is an open label, two to three center study to evaluate the clinical efficacy and safety of 1 dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes with diabetic…
- Trial name
- NCT06489340
- Testing
- 2HPβCD
- Where
- United States
- Sponsor
- ZyVersa Therapeutics, Inc.
Diabetic Kidney Disease (DKD), Type 2 Diabetes Mellitus (T2DM)
Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)
GOLD-STANDARD is a pragmatic, open-label pilot randomized controlled trial evaluating the feasibility, safety, and implementation of an early goal-directed Cardio-Kidney-Metabolic (CKM) care strategy compared with usual care in…
- Conditions
- Diabetic Kidney Disease (DKD), Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease
- Trial name
- GOLD-STANDARD (NCT07434791)
- Testing
- Early goal-directed Cardio-Kidney-Metabolic (CKM) care, Standard care (Comparison arm)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre